Brief: Eyepoint Announces Third Consecutive Positive Dsmc Recommendation For Phase 3 Wet AMD Trials For Duravyu™, Building Confidence Ahead Of Mid-2026 Topline Data
14/05/2026 12:04
EyePoint Inc EYPT.O: EYEPOINT ANNOUNCES THIRD CONSECUTIVE POSITIVE DSMC RECOMMENDATION FOR PHASE 3 WET AMD TRIALS FOR DURAVYU™, BUILDING CONFIDENCE AHEAD OF MID-2026 TOPLINE DATA EYEPOINT INC - DSMC RECOMMENDS PHASE 3 DURAVYU WET AMD TRIALS CONTINUE WITH NO MODIFICATIONS EYEPOINT INC - INTERIM PHASE 3 DATA SHOWS CONTINUED FAVORABLE SAFETY PROFILE FOR DURAVYU Source text: ID:nGNX6z9gRY Further company coverage: EYPT.O
Recent news on EyePoint
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
US STOCKS ON THE MOVE-CoreWeave, Moderna, Datadog
U.S. STOCKS ON THE MOVE-Amazon, CoreWeave, Moderna
U.S. STOCKS ON THE MOVE-Centrus Energy, Disc Medicine, Crypto
EyePoint to halve workforce after experimental drug fails second late-stage trial (updated)